Media Update: New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression 

Nitesh sinha February 23, 2023
https://ift.tt/U2aApDw

New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression 



from Sanofi - Aventis Groupe https://ift.tt/wrvamRM
via IFTTT
Tags:
Nitesh sinha

Posted by: Nitesh sinha

Post a Comment

0 Comments

Please ,
Do not enter any kind of span link